Skip to main content

Table 1 Baseline demographic characteristics

From: Presepsin and platelet to lymphocyte ratio predict the progression of septic subclinical acute kidney injury to septic acute kidney injury: a pilot study

Variable

AKI (nā€‰=ā€‰38)

Ā 

Subclinical AKI (nā€‰=ā€‰21)

p value

Age (years)

75.0 (66.0ā€“81.0)

75.0 (69.0ā€“78.0)

0.769

Sex (male) (%)

24.0 (63.2)

14.0 (66.7)

1.000

Cancer (%)

21.0 (55.3)

12.0 (57.1)

1.000

Coronary artery disease (%)

1.0 (2.6)

1.0 (4.8)

1.000

Diabetes mellitus (%)

9.0 (23.7)

1.0 (4.8)

0.157

Hypertension (%)

15.0 (39.5)

2.0 (9.5)

0.018

Albumin (g/dL)

2.3 (1.8ā€“2.9)

2.3 (2.0ā€“3.1)

0.663

CRP (mg/dL)

14.1 (7.7ā€“20.1)

9.3 (2.6ā€“13.2)

0.037

WBC (Ɨā€‰109Ā lāˆ’1)

11.6 (5.9ā€“17.5)

9.9 (5.4ā€“14.6)

0.406

Neutrophil count (Ɨā€‰109Ā lāˆ’1)

9.2 (4.2ā€“15.4)

7.2 (1.3ā€“13.5)

0.457

Lymphocyte count (Ɨā€‰109Ā lāˆ’1)

505.0 (333.5ā€“926.5)

512.0 (219.0ā€“610.0)

0.358

Plt count (Ɨā€‰104Ā mmāˆ’3)

150.0 (110.3ā€“241.8)

182.0 (126.0ā€“241.0)

0.311

Fibrinogen (mg/dL)

592.5 (348.0ā€“682.8)

613.5 (447.0ā€“736.8)

0.556

Survival (dead) (%)

16.0 (42.1)

3.0 (14.3)

0.041

ARDS (%)

10.0 (26.3)

1.0 (4.8)

0.077

Shock (%)

26.0 (68.4)

11.0 (52.4)

0.268

DIC (%)

22.0 (57.9)

4.0 (19.0)

0.006

Presepsin on Day 1 (pg/mL)

1262.0 (752.0ā€“2078.5)

707.0 (306.0ā€“1536.0)

0.019

Presepsin on Day 2 (ng/mL)

1333.0 (671.0ā€“2433.0)

797.5 (345.0ā€“1227.5)

0.038

Presepsin on Day 3 (ng/mL)

993.0 (563.0ā€“2123.0)

813.0 (478.0ā€“1827.0)

0.348

Presepsin on Day 5 (ng/mL)

1313.0 (689.0ā€“2759.0)

711.0 (410.0ā€“1055.0)

0.062

Ī”Presepsin Day 2ā€”Day 1 (pg/mL)

āˆ’Ā 65.00 (āˆ’Ā 314.0 to 507.0)

6.5 (āˆ’Ā 215.0 to 124.5)

0.959

Ī”Presepsin Day 3ā€”Day 1 (pg/mL)

āˆ’Ā 236.00 (āˆ’Ā 872.0 to 390.0)

āˆ’Ā 39.0 (āˆ’Ā 723.0 to 12.0)

0.790

Ī”Presepsin Day 5ā€”Day 1 (pg/mL)

āˆ’Ā 323.50 (āˆ’Ā 1547.5 to 719.5)

āˆ’Ā 366.5 (āˆ’Ā 762.3 to 2.8)

1.000

NGAL on Day 1 (ng/mL)

506.50 (194.7ā€“2562.0)

132.0 (54.6ā€“277.8)

Pā€‰<ā€‰0.001

NGAL on Day 2 (ng/mL)

851.20 (332.4ā€“1496.2)

140.4 (66.8ā€“271.0)

Pā€‰<ā€‰0.001

NGAL on Day 3 (ng/mL)

487.30 (225.5ā€“1212.4)

87.2 (57.4ā€“161.1)

0.003

NGAL on Day 4 (ng/mL)

630.50 (84.9ā€“1272.7)

74.8 (30.4ā€“137.6)

0.013

GPS

2.0 (1.0ā€“2.0)

1.0 (1.0ā€“2.0)

0.332

iPSā€“GPS

1.0 (1.0ā€“1.0)

1.0 (0ā€“1.0)

0.134

NLR

13.1 (4.3ā€“34.8)

16.3 (8.9ā€“27.1)

0.496

iPSā€“NLR

1.0 (0ā€“2.0)

1.0 (1.0ā€“1.0)

0.643

PLR

283.2 (170.3ā€“387.0)

401.5 (243.8ā€“855.7)

0.033

iPSā€“PLR

1.0 (0ā€“1.0)

1.0 (1.0ā€“1.0)

0.585

PI

1.0 (1.0ā€“2.0)

1.0 (0ā€“2.0)

0.281

iPSā€“PI

1.0 (0ā€“1.0)

1.0 (0ā€“1.0)

0.263

PNI

27.3 (21.3ā€“33.6)

23.3 (16.7ā€“29.5)

0.254

iPSā€“PNI

1.0 (1.0ā€“2.0)

1.0 (1.0ā€“1.0)

0.119

SOFA

9.5 (7.0ā€“11.0)

9.0 (7.0ā€“11.0)

0.930

qSOFA

2.0 (1.0ā€“3.0)

2.0 (1.0ā€“3.0)

0.599

  1. AKI acute kidney injury, CRP C-reactive protein, WBC white blood cell, ARDS acute respiratory distress syndrome, DIC disseminated intravascular coagulation, NGAL neutrophil gelatinase-associated lipocalin, GPS Glasgow Prognostic Score, iPS inflammation-presepsin score, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, PI Prognostic Index, PNI Prognostic Nutritional Index, SOFA Sequential Organ Failure Assessment, qSOFA quick Sequential Organ Failure Assessment
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us